News
HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026
HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.
Apr 23, 2026
Read more
HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation
HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.
Apr 20, 2026
Read more
HanchorBio Invited to Participate in the 19th QIC CEO Week
HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.
Apr 13, 2026
Read more
HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era
HanchorBio participated in the World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026), to be held on March 29, 2026, at the International Convention Center, Chang Yung-Fa Foundation, Taipei, Taiwan. At the conference, Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (CMO) of HanchorBio (Group), and CEO of HanchorBio US, was invited to present his clinical perspectives on CD47–SIRPα in cancer immunotherapy, as well as the latest trends in next-generation multi-checkpoint engineering.
Mar 30, 2026
Read more
HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026
HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.
Mar 20, 2026
Read more
HanchorBio Highlights Advancing HCB101 Clinical Program Across Monotherapy and Combination Settings at ESMO-TAT 2026
HanchorBio announced the presentation of updated clinical data for HCB101 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.
Mar 16, 2026
Read more
Podcast Launch: Innovations in Immuno-Oncology
HanchorBio's new and original podcast series, Innovations in Immuno-Oncology, offer listeners a closer look at the scientific rationale, business strategy, and global licensing perspectives behind next-generation immuno-oncology drug development.
Mar 11, 2026
Read more
HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026
HanchorBio will participate in Biologics World Taiwan 2026, taking place on March 25–26, 2026, at Hilton Taipei Sinban, Taiwan. During the event, HanchorBio’s Chairman and Chief Executive Officer, Dr. Scott Liu, and Executive Director of CMC, Dr. Vivian Kuo, will be invited as speakers. They will share insights on next-generation biologics innovation, spanning immuno-oncology, tri-specific Fc fusion protein development, and process and CMC excellence for emerging drug modalities.
Mar 11, 2026
Read more
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress
HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress Early clinical data show 100% ORR at 5.12 mg/kg, 100% DCR across doses, and dose-dependent tumor shrinkage; the 12 mg/kg cohort remains ongoing HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology […]
Mar 05, 2026
Read more
HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026
BIOCHINA 2026 (11th BIOCHINA Annual Conference & Expo) will be held from March 12–14, 2026 in Suzhou, China. Dr. Scott Liu, Founder, Chairman and Chief Executive Officer of HanchorBio Inc., has been invited to attend the conference and will serve as a roundtable moderator at the Antibody Drug Innovation & Development Forum, as well as participate as a featured interview and discussion speaker.Interview Topic:
“Focused Strategies in Specialized Segments — Insights from BD Transactions on the Positioning and Collaborative Strategy of Bispecific and Multispecific Antibody Innovation”
Mar 02, 2026
Read more